Bittera is under clinical development by Aardvark Therapeutics and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bittera’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bittera is under development for the treatment of metabolic disorders such as obesity and acute inflammation, chronic inflammation and Prader-Willi Syndrome. It is administered orally. The drug candidate is a TAS2R pathway modulator.
Aardvark Therapeutics overview
Aardvark Therapeutics is the US based biopharmaceutical company. The company develops small molecule therapies for treating inflammatory and metabolic diseases. It also commercializes its leading product (ARD-101).
For a complete picture of Bittera’s drug-specific PTSR and LoA scores, buy the report here.